Skip to content
DataLookout
Menu

NCT07916649

Initial and Subsequent Healthcare-Associated Infections in Intensive Care Patients

StatusActive, Not Recruiting
PhaseNot specified
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Change in Infection Site Between Index and First Subsequent Healthcare-Associated Infections
Timeframe: At diagnosis of the index healthcare-associated infection (baseline) and at diagnosis of the first subsequent healthcare-associated infection during the same ICU stay, assessed up to 120 days after baseline.
Change in Causative Microorganisms Between Index and First Subsequent Healthcare-Associated Infections
Timeframe: At diagnosis of the index healthcare-associated infection (baseline) and at diagnosis of the first subsequent healthcare-associated infection during the same ICU stay, assessed up to 120 days after baseline.

Arms and interventions

Patients With Subsequent Healthcare-Associated Infections

Adult patients who developed at least one healthcare-associated infection (HAI) during their intensive care unit (ICU) stay and subsequently experienced a new HAI during the same hospitalization. The first HAI will be defined as the index infection, and the first subsequent new HAI will be evaluated according to CDC/NHSN surveillance criteria, including the 14-day repeat infection timeframe. Clinical and microbiological characteristics of the index and subsequent infections will be compared using paired patient data. No study-specific interventions will be performed.

Patients Without Subsequent Healthcare-Associated Infections

Adult patients who developed at least one healthcare-associated infection (HAI) during their intensive care unit (ICU) stay but did not experience a subsequent new HAI during the same hospitalization. The first HAI will be defined as the index infection. Demographic and clinical characteristics at the time of the index infection will be evaluated and compared with those of patients who developed subsequent HAIs. No study-specific interventions will be performed.

Sites

1 site in 1 country

  • Dr. Abdurrahman Yurtaslan Ankara Oncology Education and Research Hospital Clinic of Anesthesiology and ReaAnkara, Yenimahalle, Turkey (Türkiye)